Abstract
Molecular-targeted therapy is to treat pathologic pathways specifically in tumor cell or tumor microenvironment. Specific molecular-targeted therapeutic agents for hormone-refractory prostate cancer (HRPC) include endothelin-A receptor antagonist, EGF receptor (EGFR) inhibitor, platelet derived growth factor receptor (PDGFR) inhibitor, nuclear factor of kappaB (NF-kappaB) inhibitor, cyclooxygenase-2 (COX2) inhibitor, and active form of Vitamin D. These agents have been investigated in clinical trials. So far, none of the above-mentioned agent has shown a sufficient clinical efficacy alone. However, docetaxel-based combinations with thalidomide or calcitriol have promising clinical activities. Further investigations are needed to optimize the molecular-targeted agents in the combinations with chemotherapeutic agents for the treatment of HRPC.
MeSH terms
-
Angiotensin Receptor Antagonists*
-
Antineoplastic Agents / therapeutic use*
-
Atrasentan
-
Benzamides
-
Boronic Acids / therapeutic use
-
Bortezomib
-
Calcitriol / therapeutic use
-
Celecoxib
-
Cyclooxygenase 2 Inhibitors / pharmacology*
-
Endothelin A Receptor Antagonists*
-
ErbB Receptors / antagonists & inhibitors*
-
Gefitinib
-
Humans
-
Imatinib Mesylate
-
Male
-
Piperazines / therapeutic use
-
Prostatic Neoplasms / drug therapy*
-
Prostatic Neoplasms / genetics
-
Prostatic Neoplasms / pathology
-
Pyrazines / therapeutic use
-
Pyrazoles / therapeutic use
-
Pyrimidines / therapeutic use
-
Pyrrolidines / therapeutic use
-
Quinazolines / therapeutic use
-
Sulfonamides / therapeutic use
-
Thalidomide / therapeutic use
-
Vitamin D / therapeutic use
Substances
-
Angiotensin Receptor Antagonists
-
Antineoplastic Agents
-
Benzamides
-
Boronic Acids
-
Cyclooxygenase 2 Inhibitors
-
Endothelin A Receptor Antagonists
-
Piperazines
-
Pyrazines
-
Pyrazoles
-
Pyrimidines
-
Pyrrolidines
-
Quinazolines
-
Sulfonamides
-
Vitamin D
-
Thalidomide
-
Bortezomib
-
Imatinib Mesylate
-
ErbB Receptors
-
Calcitriol
-
Celecoxib
-
Gefitinib
-
Atrasentan